In Brief: Boehringer Mannheim
This article was originally published in The Gray Sheet
Executive SummaryBoehringer Mannheim: Gains 510(k) clearance from FDA for the Cardiac T Rapid Assay, a point-of-care version of its troponin-T test. Boehringer has marketed a troponin-T assay -- used to help diagnose myocardial infarction -- on its ES 300 ELISA immunoassay system since June 1994. The Cardiac T Rapid Assay has been sold in Europe as the Trop T Rapid Assay since September 1994...
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.